PAB's 'mouse' history is a clasdic example of traders making the most of an opportunity but getting less and less bang for their buck as successful pre-clinical trials go by.
Each successive 'success', becomes more and more predictable, as it becomes obvious that mice respond to the drug.
The real crunch can only come post the first human trials and there is much water (and expenditiure) to pass under the bridge between now and then.
IMO, the current market cap is fair and not the result of market manipulation. I would be very wary of a simple 'spike, then back down she goes, so time to accumulate' approach.
You can only have so much of a 'good thing', before it becomes a risk/reward trap.
Human trials are the biggie, starting with a P1, but more importantly a successful P2, which at this stage is a long, long way off. In the meantime, it will be a traders stock, as distinct from a prudent accumulator's stock.
PAB Price at posting:
2.5¢ Sentiment: Hold Disclosure: Held
